background there is substantial interest in chocolate and flavan3ols for the prevention of cardiovascular disease cvdobjective the objective was to systematically review the effects of chocolate cocoa and flavan3ols on major cvd risk factorsdesign we searched medline embase and cochrane databases for randomized controlled trials rcts of chocolate cocoa or flavan3olswe contacted authors for additional data and conducted duplicate assessment of study inclusion data extraction validity and randomeffects metaanalysesresults we included 42 acute or shortterm chronic 18 wk rcts that comprised 1297 participantsinsulin resistance homair 067 95 ci 098 036 was improved by chocolate or cocoa due to significant reductions in serum insulinflowmediated dilatation fmd improved after chronic 134 95 ci 100 168 and acute 319 95 ci 204 433 intakeseffects on homair and fmd remained stable to sensitivity analyseswe observed reductions in diastolic blood pressure bp 160 mm hg 95 ci 277 043 mm hg and mean arterial pressure 164 mm hg 95 ci 327 001 mm hg and marginally significant effects on ldl 007 mmoll 95 ci 013 000 mmoll and hdl 003 mmoll 95 ci 000 006 mmoll cholesterolchocolate or cocoa improved fmd regardless of the dose consumed whereas doses 50 mg epicatechind resulted in greater effects on systolic and diastolic bpgrade grading of recommendations assessment development and evaluation a tool to assess quality of evidence and strength of recommendations suggested low to moderatequality evidence of beneficial effects with no suggestion of negative effectsthe strength of evidence was lowered due to unclear reporting for allocation concealment dropouts missing data on outcomes and heterogeneity in biomarker results in some studiesconclusions we found consistent acute and chronic benefits of chocolate or cocoa on fmd and previously unreported promising effects on insulin and homairlarger longerduration and independently funded trials are required to confirm the potential cardiovascular benefits of cocoa flavan3ols